• Cereno Scientific will attend the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14-16, 2026.
• CEO Sten R. Sörensen is scheduled for in-person one-on-one meetings with US and international investors during the conference.
• The appearance comes as the EPIMODE Phase IIb trial of PAH candidate CS1 continues, with patient screening underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.